17
Zwitterionic cocrystal of diclofenac and L- proline: Structure determination, solubility, kinetics of cocrystallization, and stability study By Dwi Utami WORD COUNT 6259 TIME SUBMITTED 18-DEC-2020 11:01PM PAPER ID 66981359

study kinetics of cocrystallization, and stability proline: Structure … · 2020. 12. 23. · N. Jagadeesh Babu, Ashwini Nangia. "Solubility Advantage of Amorphous Drugs and Pharmaceutical

  • Upload
    others

  • View
    4

  • Download
    0

Embed Size (px)

Citation preview

Page 1: study kinetics of cocrystallization, and stability proline: Structure … · 2020. 12. 23. · N. Jagadeesh Babu, Ashwini Nangia. "Solubility Advantage of Amorphous Drugs and Pharmaceutical

Zwitterionic cocrystal of diclofenac and L-proline: Structure determination, solubility,kinetics of cocrystallization, and stability

studyBy Dwi Utami

WORD COUNT 6259 TIME SUBMITTED 18-DEC-2020 11:01PM

PAPER ID 66981359

Page 2: study kinetics of cocrystallization, and stability proline: Structure … · 2020. 12. 23. · N. Jagadeesh Babu, Ashwini Nangia. "Solubility Advantage of Amorphous Drugs and Pharmaceutical
Page 3: study kinetics of cocrystallization, and stability proline: Structure … · 2020. 12. 23. · N. Jagadeesh Babu, Ashwini Nangia. "Solubility Advantage of Amorphous Drugs and Pharmaceutical
Page 4: study kinetics of cocrystallization, and stability proline: Structure … · 2020. 12. 23. · N. Jagadeesh Babu, Ashwini Nangia. "Solubility Advantage of Amorphous Drugs and Pharmaceutical
Page 5: study kinetics of cocrystallization, and stability proline: Structure … · 2020. 12. 23. · N. Jagadeesh Babu, Ashwini Nangia. "Solubility Advantage of Amorphous Drugs and Pharmaceutical
Page 6: study kinetics of cocrystallization, and stability proline: Structure … · 2020. 12. 23. · N. Jagadeesh Babu, Ashwini Nangia. "Solubility Advantage of Amorphous Drugs and Pharmaceutical
Page 7: study kinetics of cocrystallization, and stability proline: Structure … · 2020. 12. 23. · N. Jagadeesh Babu, Ashwini Nangia. "Solubility Advantage of Amorphous Drugs and Pharmaceutical
Page 8: study kinetics of cocrystallization, and stability proline: Structure … · 2020. 12. 23. · N. Jagadeesh Babu, Ashwini Nangia. "Solubility Advantage of Amorphous Drugs and Pharmaceutical
Page 9: study kinetics of cocrystallization, and stability proline: Structure … · 2020. 12. 23. · N. Jagadeesh Babu, Ashwini Nangia. "Solubility Advantage of Amorphous Drugs and Pharmaceutical
Page 10: study kinetics of cocrystallization, and stability proline: Structure … · 2020. 12. 23. · N. Jagadeesh Babu, Ashwini Nangia. "Solubility Advantage of Amorphous Drugs and Pharmaceutical
Page 11: study kinetics of cocrystallization, and stability proline: Structure … · 2020. 12. 23. · N. Jagadeesh Babu, Ashwini Nangia. "Solubility Advantage of Amorphous Drugs and Pharmaceutical

13%SIMILARITY INDEX

1

2

3

4

5

6

7

Zwitterionic cocrystal of diclofenac and L-proline: Structuredetermination, solubility, kinetics of cocrystallization, andstability studyORIGINALITY REPORT

PRIMARY SOURCES

Andrew V. Trask, W. D. Samuel Motherwell, WilliamJones. "Pharmaceutical Cocrystallization: Engineeringa Remedy for Caffeine Hydration", Crystal Growth & Design, 2005Crossref

Artem O. Surov, Alexander P. Voronin, Alex N. Manin,Nikolay G. Manin et al. "Pharmaceutical Cocrystals ofDiflunisal and Diclofenac with Theophylline", MolecularPharmaceutics, 2014Crossref

www.selleck.jpInternet

Cecilia C. P. da Silva, Bolaji C. Dayo Owoyemi,Benedito R. Alvarenga-Jr, Natalia Alvarez, JavierEllena, Renato L. Carneiro. "Synthesis and solid-statecharacterization of diclofenac imidazolium monohydrate: animidazolium pharmaceutical ionic liquid", CrystEngComm, 2020Crossref

www.freepatentsonline.comInternet

29g02Internet

www.researchgate.netInternet

66 words — 1%

31 words — 1%

21 words — < 1%

19 words — < 1%

19 words — < 1%

17 words — < 1%

17 words — < 1%

Page 12: study kinetics of cocrystallization, and stability proline: Structure … · 2020. 12. 23. · N. Jagadeesh Babu, Ashwini Nangia. "Solubility Advantage of Amorphous Drugs and Pharmaceutical

8

9

10

11

12

13

14

15

epdf.pubInternet

Sharmarke Mohamed, Durga Prasad Karothu,Panče Naumov. "Using crystal structure predictionto rationalize the hydration propensities of substituted adamantanehydrochloride salts", Acta Crystallographica Section B StructuralScience, Crystal Engineering and Materials, 2016Crossref

Kevin P. O’Donnell, Robert O. Williams. "Chapter 2Optimizing the Formulation of Poorly Water-SolubleDrugs", Springer Science and Business Media LLC, 2012Crossref

Stimac, Vlado, Maja Matanovic Skugor, Ivana PalejJakopovic, Adrijana Vinter, Marina Ilijas, SulejmanAlihodzic, and Stjepan Mutak. "Initial Scale-Up and ProcessImprovements for the Preparation of a Lead AntibacterialMacrolone Compound", Organic Process Research &Development, 2010.Crossref

doaj.orgInternet

cora.ucc.ieInternet

Koji Shiraki. "Dissolution Improvement and theMechanism of the Improvement fromCocrystallization of Poorly Water-soluble Compounds",Pharmaceutical Research, 11/2008Crossref

Sampada A. Koranne, Anasuya Sahoo, Joseph F.Krzyzaniak, Suman Luthra, Kapildev K Arora, RajSuryanarayanan. "Challenges in transitioning cocrystals frombench to bedside: Dissociation in prototype drug productenvironment", Molecular Pharmaceutics, 2018Crossref

17 words — < 1%

16 words — < 1%

15 words — < 1%

15 words — < 1%

14 words — < 1%

13 words — < 1%

13 words — < 1%

12 words — < 1%

12 words — < 1%

Page 13: study kinetics of cocrystallization, and stability proline: Structure … · 2020. 12. 23. · N. Jagadeesh Babu, Ashwini Nangia. "Solubility Advantage of Amorphous Drugs and Pharmaceutical

16

17

18

19

20

21

22

23

24

25

26

mafiadoc.comInternet

www.scipharm.atInternet

jddtonline.infoInternet

N. Jagadeesh Babu, Ashwini Nangia. "SolubilityAdvantage of Amorphous Drugs andPharmaceutical Cocrystals", Crystal Growth & Design, 2011Crossref

pt.scribd.comInternet

nanoscalereslett.springeropen.comInternet

chemistry-europe.onlinelibrary.wiley.comInternet

Hongyan He, Ying Huang, Qi Zhang, Jian-RongWang, Xuefeng Mei. "Zwitterionic Cocrystals ofFlavonoids and Proline: Solid-State Characterization,Pharmaceutical Properties, and Pharmacokinetic Performance",Crystal Growth & Design, 2016Crossref

Advances in Organic Crystal Chemistry, 2015.Crossref

Tejender S. Thakur, Ranjit Thakuria. "CrystallineMulticomponent Solids: An Alternative forAddressing the Hygroscopicity Issue in Pharmaceutical Materials",Crystal Growth & Design, 2020Crossref

scholarbank.nus.edu.sgInternet

12 words — < 1%

12 words — < 1%

12 words — < 1%

11 words — < 1%

11 words — < 1%

11 words — < 1%

11 words — < 1%

11 words — < 1%

10 words — < 1%

10 words — < 1%

10 words — < 1%

Page 14: study kinetics of cocrystallization, and stability proline: Structure … · 2020. 12. 23. · N. Jagadeesh Babu, Ashwini Nangia. "Solubility Advantage of Amorphous Drugs and Pharmaceutical

27

28

29

30

31

32

33

34

35

Jaswanth S. Bhandaru, Narender Malothu, Raghuram R.Akkinepally. "Characterization and Solubility Studiesof Pharmaceutical Cocrystals of EprosartanMesylate", Crystal Growth & Design, 2015Crossref

Anaelle Tilborg, Andrea Carletta, Johan Wouters."Structural and energy insights on solid-statecomplexes with trimethoprim: a combined theoretical andexperimental investigation", Acta Crystallographica Section BStructural Science, Crystal Engineering and Materials, 2015Crossref

www.jstage.jst.go.jpInternet

Babulal Das, Jubaraj B. Baruah. "SupramolecularSynthons and Hydrates in Stabilization ofMulticomponent Crystals of Nicotinamide and Isonicotinamide withN-Containing Aromatic Dicarboxylic Acids", Crystal Growth &Design, 2011Crossref

www.intechopen.comInternet

Shan-Yang Lin, Hong-Liang Lin, Ying-Ting Chi, Ru-Ying Hung, Yu-Ting Huang, Wei-Hsien Hsieh, Chi-YuKao. "Influence of Soluplus on Solid-State Properties and PhysicalStability of Indomethacin-Saccharin Co-crystal Formation Preparedby Air-Drying Process", Journal of Pharmaceutical Innovation,2016Crossref

physoc.onlinelibrary.wiley.comInternet

silvafennica.fiInternet

authors.library.caltech.eduInternet

10 words — < 1%

10 words — < 1%

9 words — < 1%

9 words — < 1%

9 words — < 1%

9 words — < 1%

9 words — < 1%

9 words — < 1%

9 words — < 1%

Page 15: study kinetics of cocrystallization, and stability proline: Structure … · 2020. 12. 23. · N. Jagadeesh Babu, Ashwini Nangia. "Solubility Advantage of Amorphous Drugs and Pharmaceutical

36

37

38

39

40

41

42

43

44

www.pre8.enveng.tuc.grInternet

Luis Padrela, Edmundo Gomes de Azevedo, SitaramP. Velaga. "Powder X-ray diffraction method for thequantification of cocrystals in the crystallization mixture", DrugDevelopment and Industrial Pharmacy, 2011Crossref

www.scielo.brInternet

Elna Pidcock. " Spatial arrangement of molecules inhomomolecular ' = 2 structures ", ActaCrystallographica Section B Structural Science, 2006Crossref

www.journal.csj.jpInternet

Kamal Kumar Bisht, Priyank Patel, Yadagiri Rachuri,Suresh Eringathodi. "Binary co-crystals of the activepharmaceutical ingredient 1,4-bis(4-pyridyl)-2,3-diaza-1,3-butadiene and camphoric acid", Acta Crystallographica Section BStructural Science, Crystal Engineering and Materials, 2014Crossref

Anaëlle Tilborg, Tom Leyssens, Bernadette Norberg,Johan Wouters. "Structural Study ofProlinium/Fumaric Acid Zwitterionic Cocrystals: Focus onHydrogen-Bonding Pattern Involving Zwitterionic (Ionic)Heterosynthons", Crystal Growth & Design, 2013Crossref

Rosa Pireddu, Chiara Sinico, Guido Ennas, MicheleSchlich et al. "The effect of diethylene glycolmonoethyl ether on skin penetration ability of diclofenac acidnanosuspensions", Colloids and Surfaces B: Biointerfaces, 2018Crossref

dro.dur.ac.ukInternet

8 words — < 1%

8 words — < 1%

8 words — < 1%

8 words — < 1%

8 words — < 1%

8 words — < 1%

8 words — < 1%

8 words — < 1%

8 words — < 1%

Page 16: study kinetics of cocrystallization, and stability proline: Structure … · 2020. 12. 23. · N. Jagadeesh Babu, Ashwini Nangia. "Solubility Advantage of Amorphous Drugs and Pharmaceutical

45

46

47

48

49

50

51

52

Amjad M. Qandil, Shereen M. Assaf, Enas A. Al Ani,Alaa Eldeen Yassin, Aiman A. Obaidat. "Sustained-release diclofenac potassium orally disintegrating tabletincorporating eudragit ERL/ERS: possibility of specific diclofenac-polymer interaction", Journal of Pharmaceutical Investigation, 2013Crossref

Seiichiro Izawa, Kyohei Nakano, Kaori Suzuki, YujiaoChen et al. "Crystallization and Polymorphism ofOrganic Semiconductor in Thin Film Induced by SurfaceSegregated Monolayers", Scientific Reports, 2018Crossref

Kashyap Kumar Sarmah, Pranamika Sarma,Dharmaraj R. Rao, Poonam Gupta, Naba K. Nath,Mihails Arhangelskis, Ranjit Thakuria. "MechanochemicalSynthesis of Olanzapine Salts and Their Hydration Stability StudyUsing Powder X-ray Diffraction", Crystal Growth & Design, 2018Crossref

Lai, F.. "Diclofenac nanosuspensions: Influence ofpreparation procedure and crystal form on drugdissolution behaviour", International Journal ofPharmaceutics, 20090521Crossref

Springer Theses, 2016.Crossref

Diana N. Evtushenko, Sergey G. Arkhipov, AlexanderV. Fateev, Tatyana I. Izaak et al. " A cocrystal of -ascorbic acid with picolinic acid: the role of O—H...O, N—H...Oand C—H...O hydrogen bonds and -ascorbic acid conformation instructure stabilization ", Acta Crystallographica Section BStructural Science, Crystal Engineering and Materials, 2020Crossref

www.science.govInternet

Dejia Ma, Tiezhu Pei, Yunhe Bai, Lina Zhou, Ying Bao, Qiuxiang

8 words — < 1%

8 words — < 1%

8 words — < 1%

8 words — < 1%

8 words — < 1%

8 words — < 1%

8 words — < 1%

7 words — < 1%

Page 17: study kinetics of cocrystallization, and stability proline: Structure … · 2020. 12. 23. · N. Jagadeesh Babu, Ashwini Nangia. "Solubility Advantage of Amorphous Drugs and Pharmaceutical

53

EXCLUDE QUOTES ON

EXCLUDEBIBLIOGRAPHY

ON

EXCLUDE MATCHES OFF

Yin, Chuang Xie. "Salts formation between ibuprofenand pyridine derivatives: Effect of amino group onsupramolecular packing and proton transfer", Journalof Molecular Structure, 2019Crossref

www.hindawi.comInternet

7 words — < 1%

7 words — < 1%